GLP1-SARCO
Evaluation of the Relationship Between GLP-1 Receptor Agonist Use and Sarcopenia in Non-Diabetic Obese Individuals: A Prospective Descriptive Study
Sponsor study identifier
observational
42
1 country
1
Study Start
May 30, 2026
Actual (reported)Primary Completion
November 30, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 30, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity. Evidence in non-diabetic obese individuals is limited and inconsistent. This prospective descriptive study will assess muscle mass, muscle strength, physical performance and sarcopenia risk in non-diabetic obese adults starting GLP-1 RA therapy, at baseline and at month 3, and will examine how weight loss relates to changes in body composition.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 30, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 30, 2026
Actual (reported)September 29, 2026
Actual (reported)October 5, 2026
Actual (reported)November 30, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
November 30, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change in SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls) total score
SARC-F is a 5-item sarcopenia screening questionnaire. Total score ranges from 0 to 10, and higher scores indicate a worse outcome (greater risk of sarcopenia). Change = month 3 score minus baseline score, reported in points on the scale.
Baseline (GLP-1 RA initiation) and 3 months
Number of participants with a positive SARC-F screening result
Baseline and 3 months
Change in handgrip strength
baseline and 3 months.
Adults (≥18 years) with BMI ≥30 kg/m² and no diabetes who start GLP-1 RA treatment under routine clinical care and are followed at the Diabetes Education Unit.
GLP-1 receptor agonist (GLP-1 RA) or dual GLP-1/GIP receptor agonist (e.g., semaglutide, tirzepatide) prescribed by the treating physician as routine clinical care for obesity in adults without diabetes. The agent, dose and duration are determined by the treating physician; the study does not assign, supply or modify treatment. Participants are enrolled at GLP-1 RA initiation and followed for 3 months at the Diabetes Education Unit. Study-specific assessments at baseline and month 3: SARC-F questionnaire, handgrip strength (hydraulic dynamometer), five-times chair stand test and 4-metre gait speed. Body composition by bioelectrical impedance analysis (skeletal muscle mass index, fat mass) and routine laboratory results are taken from standard clinical follow-up; no additional blood tests are requested.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adults with obesity and no diabetes referred from the Endocrinology and Metabolism and Internal Medicine outpatient clinics to the Diabetes Education Unit and using a GLP-1 RA.
Kanuni Sultan Süleyman Training and Research Hospital
Istanbul, Kucukcekmece, Turkey (Türkiye)
Aroda VR, Erhan U, Jelnes P, Meier JJ, Abildlund MT, Pratley R, Vilsboll T, Husain M. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes Obes Metab. 2023 May;25(5):1385-1397. doi: 10.1111/dom.14990. Epub 2023 Feb 21.
Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab (Seoul). 2019 Sep;34(3):247-262. doi: 10.3803/EnM.2019.34.3.247.
First Submitted
September 29, 2026
First Posted
October 5, 2026
Study Start
May 30, 2026
Actual (reported)Primary Completion
November 30, 2026
EstimatedEffect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle
Contact the study team to confirm eligibility.
Silver HJ, Olson D, Mayfield D, Wright P, Nian H, Mashayekhi M, Koethe JR, Niswender KD, Luther JM, Brown NJ. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab. 2023 Aug;25(8):2340-2350. doi: 10.1111/dom.15113. Epub 2023 May 15.
Damluji AA, Alfaraidhy M, AlHajri N, Rohant NN, Kumar M, Al Malouf C, Bahrainy S, Ji Kwak M, Batchelor WB, Forman DE, Rich MW, Kirkpatrick J, Krishnaswami A, Alexander KP, Gerstenblith G, Cawthon P, deFilippi CR, Goyal P. Sarcopenia and Cardiovascular Diseases. Circulation. 2023 May 16;147(20):1534-1553. doi: 10.1161/CIRCULATIONAHA.123.064071. Epub 2023 May 15.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
November 30, 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 8, 2026
Record last verified: 2026-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: